Middle East respiratory syndrome coronavirus (MERS-CoV): Challenges inidentifying its source and controlling its spread

Microbes and Infection

Volumn 15, Issue 8-9, 2013, Pages 625-629

  Lu, Lu ^a   Liu, Qi ^a   Du, Lanying ^b   Jiang, Shibo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

Coronavirus; MERS CoV; SARS CoV; Source; Therapeutics; Vaccine

Indexed keywords

INTERFERON; LOPINAVIR; RIBAVIRIN; VIRUS VACCINE;

ANTIVIRAL THERAPY; CORONAVIRUS; CORONAVIRUS INFECTION; HUMAN; INFECTION PREVENTION; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION;

CORONAVIRUS; SARS CORONAVIRUS;

EID: 84880609399     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.06.003     Document Type: Short Survey

References (44)

1. A.M. Zaki, Novel Cornavirus - Saudi Arabia: Human Isolate, (accessed 09.06.13). http://www.promedmail.org/direct.php%3fid%3d20120920.1302733.
2. WHO, Novel Coronavirus Infection in the United Kingdom, (accessed 09.06.13). http://www.who.int/csr/don/2012_09_23/en/index.html.
3. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367:1814-1820.
4. de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., Fouchier R.A., Galiano M., Gorbalenya A.E., Memish Z., Perlman S., Poon L.L., Snijder E.J., Stephens G.M., Woo P.C., Zaki A.M., Zambon M., Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV); announcement of the coronavirus study group. J. Virol. 15 May 2013, (Epub ahead of print).
5. WHO, Novel Coronavirus Infection - Update (Middle East Respiratory Syndrome-coronavirus), (accessed 09.06.13). http://www.who.int/csr/don/2013_06_07/en/index.html.
6. Centers for Disease Control and Prevention, Update, Case Definitions, and Guidance - MERS Update, (accessed 09.06.13). http://www.cdc.gov/coronavirus/mers/case-def.html.
7. Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W., Nicholls J., Yee W.K.S., Yan W.W., Cheung M.T., Cheng V.C.C., Chan K.H., Tsang D.N.C., Yung R.W.H., Ng T.K., Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361:1319-1325.
8. Zhong N.S., Zheng B.J., Li Y.M., Poon L.L.M., Xie Z.H., Chan K.H., Li P.H., Tan S.Y., Chang Q., Xie J.P., Liu X.Q., Xu J., Li D.X., Yuen K.Y., Peiris J.S.M., Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003, 362:1353-1358.
9. Drosten C., Gunther S., Preiser W., van der W.S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348:1967-1976.
10. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S.X., Tamin A., Lowe L., Frace M., Derisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300:1394-1399.
11. M. Chan, WHO Director-General Praises the World Health Assembly for its Work, (accessed 09.06.13). http://www.who.int/dg/speeches/2013/world_health_assembly_20130527/en/index.html.
12. M.R. Wilson, Administration Declares Mideast Flu a Potential Public Health Emergency, (accessed 09.06.13). http://thehill.com/blogs/healthwatch/public-global-health/303441-administration-declares-mideast-flu-a-public-health-emergency#ixzz2VLnzfH16.
13. Department of Health and Human Services, Determination and Declaration Regarding emergency Use of inVitro Diagnostics for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), (accessed 09.06.13). http://www.gpo.gov/fdsys/pkg/FR-2013-06-05/html/2013-13333.htm.
14. Tanquintic-Misa E. Saudi Arabia Moves to Control MERS-CoV before Mecca Hajj Pilgrimage Season 6 June 2013, (Ref Type: Report). http://www.ibtimes.co.uk/articles/475277/20130606/saudi-mers-cov-mecca-hajj.htm.
15. Lau S.K., Li K.S., Tsang A.K., Lam C.S., Ahmed S., Chen H., Chan K.H., Woo P.C., Yuen K.Y. Genetic characterization of betacoronavirus lineage C viruses in bats revealed marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications on the origin of the novel Middle East respiratory syndrome coronavirus. J. Virol. 29 May 2013, (Epub ahead of print).
16. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., Muth D., Demmers J.A., Zaki A., Fouchier R.A., Thiel V., Drosten C., Rottier P.J., Osterhaus A.D., Bosch B.J., Haagmans B.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
17. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009, 7:226-236.
18. Chan J.F., Chan K.H., Choi G.K., To K.K., Tse H., Cai J.P., Yeung M.L., Cheng V.C., Chen H., Che X.Y., Lau S.K., Woo P.C., Yuen K.Y. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 2013, 207:1743-1752.
19. Buchholz U., Muller M.A., Nitsche A., Sanewski A., Wevering N., Bauer-Balci T., Bonin F., Drosten C., Schweiger B., Wolff T., Muth D., Meyer B., Buda S., Krause G., Schaade L., Haas W. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro. Surveill. 2013, 18. pii: 20406.
20. Deming D., Sheahan T., Heise M., Yount B., Davis N., Sims A., Suthar M., Harkema J., Whitmore A., Pickles R., West A., Donaldson E., Curtis K., Johnston R., Baric R. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006, 3:e525.
21. Yasui F., Kai C., Kitabatake M., Inoue S., Yoneda M., Yokochi S., Kase R., Sekiguchi S., Morita K., Hishima T., Suzuki H., Karamatsu K., Yasutomi Y., Shida H., Kidokoro M., Mizuno K., Matsushima K., Kohara M. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 2008, 181:6337-6348.
22. Bolles M., Deming D., Long K., Agnihothram S., Whitmore A., Ferris M., Funkhouser W., Gralinski L., Totura A., Heise M., Baric R.S. A double-inactivated SARS-CoV vaccine provides incomplete protection in mice and induces increased eosinophilic pro-inflammatory pulmonary response upon challenge. J. Virol. 2011, 85(23):12201-12215.
23. Tseng C.T., Sbrana E., Iwata-Yoshikawa N., Newman P.C., Garron T., Atmar R.L., Peters C.J., Couch R.B. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012, 7:e35421.
24. Jaume M., Yip M.S., Kam Y.W., Cheung C.Y., Kien F., Roberts A., Li P.H., Dutry I., Escriou N., Daeron M., Bruzzone R., Subbarao K., Peiris J.S., Nal B., Altmeyer R. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 2012, 18(Suppl. 2):31-36.
25. He Y., Lu H., Siddiqui P., Zhou Y., Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 2005, 174:4908-4915.
26. Jiang S., Bottazzi M.E., Du L., Lustigman S., Tseng C.T., Curti E., Jones K., Zhan B., Hotez P.J. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev. Vaccines 2012, 11:1405-1413.
27. Jiang S., Lu L., Du L., Debnath A.K. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J. Infect. 2013, 66:464-466.
28. Chan K.H., Chan J.F., Tse H., Chen H., Lau C.C., Cai J.P., Tsang A.K., Xiao X., To K.K., Lau S.K., Woo P.C., Zheng B.J., Wang M., Yuen K.Y. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J. Infect. 10 Apr 2013, (Epub ahead of print), pii: S0163-4453(13)00071-6. 10.1016/j.jinf.2013.03.015.
29. Du L., Ma C., Jiang S. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J. Infect. 16 May 2013, (Epub ahead of print).
30. Brogan T.V., Thiagarajan R.R., Rycus P.T., Bartlett R.H., Bratton S.L. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med. 2009, 35:2105-2114.
31. Stockman L.J., Bellamy R., Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006, 3:e343.
32. Cheng V.C., Lau S.K., Woo P.C., Yuen K.Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 2007, 20:660-694.
33. Kindler E., Jonsdottir H.R., Muth D., Hamming O.J., Hartmann R., Rodriguez R., Geffers R., Fouchier R.A., Drosten C., Muller M.A., Dijkman R., Thiel V. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. mBio 2013, 4:e00611-e00612.
34. Osterholm M.T. Preparing for the next pandemic. N. Engl. J. Med. 2005, 352:1839-1842.
35. Huang K.J., Su I.J., Theron M., Wu Y.C., Lai S.K., Liu C.C., Lei H.Y. An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 2005, 75:185-194.
36. Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012, 76:16-32.
37. Josset L., Menachery V.D., Gralinski L.E., Agnihothram S., Sova P., Carter V.S., Yount B.L., Graham R.L., Baric R.S., Katze M.G. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 2013, 4.
38. Chan J.F., Li K.S., To K.K., Cheng V.C., Chen H., Yuen K.Y. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. J. Infect. 2012, 65:477-489.
39. Jiang S., Lin K., Strick N., Neurath A.R. HIV-1 inhibition by a peptide. Nature 1993, 365:113.
40. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9770-9774.
41. Kilby J.M., Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 2003, 348:2228-2238.
42. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348:2175-2185.
43. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., Xiong H., Farmar J., Debnath A.K., Tien P., Jiang S. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004, 363:938-947.
44. Liu S., Wu S., Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 2007, 13:143-162.